PROTACpedia
The search can be performed by various parameters such as Target name, UniProt ID, SMILES substructure or by various details regarding a publication.
Note that it is possible to narrow down the search results by querying several fields simultaneously.

The resulting PROTAC images are color coded: green - E3 binder, red - linker, blue - target binding ligand.
If you find this web server of interest, please also try PRosettaC.
Gene or Target name
UniProt Id
Ligand name
E3 Ligase
E3 Binder
PROTAC SMILES (substructure)
PROTAC Name
Author
Year
Pubmed or Patent number
Curator
Algorithm and overview: Nir London (nir.london@weizmann.ac.il)
Server: Jaime Prilusky (jaime.prilusky@weizmann.ac.il)
3 Representative
+60 Active PROTACs
+10 Inactive PROTACs
 DetailsDC50DmaxSource
= 50 nM= 85 % Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-XL. Chem Commun (Camb). 2019 Dec 5;55(98):14765-14768. PMID:31754664 DOI:10.1039/c9cc07217a
= 2.5 nM Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
= 4.5 nM Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
= 6.3 nM Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
= 10.6 nM Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
= 53 nM~ 100 % Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
= 71 nM Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
= 93 nM~ 90 % Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. PMID:32145645 DOI:10.1016/j.ejmech.2020.112186
= 46 nM= 96.2 % Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. Nat Commun. 2020 Apr 24;11(1):1996. PMID:32332723 DOI:10.1038/s41467-020-15838-0
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines. Eur J Med Chem. 2020 Aug 1;199:112397. PMID:32388279 DOI:10.1016/j.ejmech.2020.112397
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines. Eur J Med Chem. 2020 Aug 1;199:112397. PMID:32388279 DOI:10.1016/j.ejmech.2020.112397
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines. Eur J Med Chem. 2020 Aug 1;199:112397. PMID:32388279 DOI:10.1016/j.ejmech.2020.112397
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines. Eur J Med Chem. 2020 Aug 1;199:112397. PMID:32388279 DOI:10.1016/j.ejmech.2020.112397
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines. Eur J Med Chem. 2020 Aug 1;199:112397. PMID:32388279 DOI:10.1016/j.ejmech.2020.112397
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines. Eur J Med Chem. 2020 Aug 1;199:112397. PMID:32388279 DOI:10.1016/j.ejmech.2020.112397
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines. Eur J Med Chem. 2020 Aug 1;199:112397. PMID:32388279 DOI:10.1016/j.ejmech.2020.112397
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines. Eur J Med Chem. 2020 Aug 1;199:112397. PMID:32388279 DOI:10.1016/j.ejmech.2020.112397
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines. Eur J Med Chem. 2020 Aug 1;199:112397. PMID:32388279 DOI:10.1016/j.ejmech.2020.112397
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines. Eur J Med Chem. 2020 Aug 1;199:112397. PMID:32388279 DOI:10.1016/j.ejmech.2020.112397
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines. Eur J Med Chem. 2020 Aug 1;199:112397. PMID:32388279 DOI:10.1016/j.ejmech.2020.112397
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines. Eur J Med Chem. 2020 Aug 1;199:112397. PMID:32388279 DOI:10.1016/j.ejmech.2020.112397
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines. Eur J Med Chem. 2020 Aug 1;199:112397. PMID:32388279 DOI:10.1016/j.ejmech.2020.112397
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines. Eur J Med Chem. 2020 Aug 1;199:112397. PMID:32388279 DOI:10.1016/j.ejmech.2020.112397
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines. Eur J Med Chem. 2020 Aug 1;199:112397. PMID:32388279 DOI:10.1016/j.ejmech.2020.112397
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines. Eur J Med Chem. 2020 Aug 1;199:112397. PMID:32388279 DOI:10.1016/j.ejmech.2020.112397